Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC-Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation).
ÌÇÐÄ´«Ã½
NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC-Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation). Kong, F., Hu, C., Ten Haken, R., Xiao, Y., Matuszak, M., Hirsh, V., Pryma, D. A., Siegel, B. A., Gelblum, D. Y., Hayman, J., Robinson, C., Loo, B. W., Videtic, G. M., Faria, S., Ferguson, C., Dunlap, N. E., Kundapur, V., Paulus, R., Bradley, J. D., Machtay, M. LIPPINCOTT WILLIAMS & WILKINS. 2021View details for
View details for